Hispanics study

Dq artment of Hispanic Studies, University of Glasgow, Scotland... 

The mean maternal age for the 12 mothers included in this study was 25.8 years, with a range of 20 to 31 years. Mother s race was 75 percent black, 17 percent white, and 8 percent Hispanic. All were low income. Eighty-three percent of the women were multiparas with an average of 5.2 previous pregnancies and 2.7 live births. 

Anemia is a common condition, and the prevalence of anemia varies widely based on age, gender, race/ethnicity, and comorbid conditions. A study of anemia prevalence in a nationally representative sample of community-dwelling individuals describes how anemia differs across different populations.1 The prevalence of anemia in children (ages 1-16 years) was 6% to 9%, but the prevalence of anemia increases to approximately 11% in adults over age 65 years and to at least 20% in adults 85 years of age and older. Anemia is generally more common in women, particularly during their reproductive years (ages 17-49 years), when anemia occurs in over 12%, but in less than 2% of men. The same study showed that in the population over age 65, non-Hispanic whites and Mexican Americans had similar prevalence of anemia (9.0% and 10.4%, respectively), but with a prevalence of 27.8%, anemia was significantly more common in non-Hispanic blacks. 

Chiu et al, 1992 Lin Finder, 1983 Lin et al, 1988b Potkin et al, 1984 Lin etal., 1989 Ruiz et al, 1996 Jann et al, 1989 Jann etal, 1992 Zhang-Wong etal., 1998). The majority of these studies were carried out with haloperidol. A number of studies examined differences between Caucasians and Hispanics, and African Americans and Caucasians (Midha et al., 1988b Midha etal, 1988a Ruiz et al., 1996). In general these studies provided mixed results. Another noteworthy feature of the research literature is that there appear to be no studies that have considered ethnic differences in pharmacokinetics and response for the depot antipsychotics. This may be an artifact of the low levels of depot prescribing found in the US, China, and Japan. 

Early landmark studies utilizing Hispanic subjects in the 1980s (Escobar Tuason, 1980 Marcos Cancro, 1982) compared the efficacy and response of several tricyclic antidepressants to placebo. They were the first to hint at a possible heightened placebo response in Hispanics and they suggested that certain Hispanic subjects... 

An open-label study of paroxetine and fluoxetine (Alonso et al, 1997) in depressed Hispanic (Mexican descent, n = 13) and non-Hispanic females (n = 13) showed no differences in response rates. At variance with the tricyclic data, Hispanic subjects complained of fewer side effects (2.2 2.0 vs. 5.1 2.5 p < 0.005), but twice as many terminated participation prior to study completion due to non-compliance, intolerable side effects or pregnancy. 

A small, flexible dose study of citalopram (dosage range = 10-40 mg/day) in 14 Hispanic and 6 non-Hispanic (non-White) depressed HIV-positive patients conducted in Miami also showed no differences in response rate or effective dose between ethnicities (Currier etal., 2004). In addition, Hispanic patients did not have a significantly higher attrition rate compared to non-Hispanics. 

Another study with citalopram evaluated its efficacy in the treatment of social anxiety disorder along with co-morbid major depression (Schneier etal., 2003). The outpatients (n= 21) were predominantly Hispanic (76%) and from New York. Response rates for the intent-to-treat sample were 66.7% for social anxiety disorder and 76.2% for major depression. Only one subject was known to have withdrawn secondary to severe side effects. The mean dose of the medication was 37.6 mg/day and there was no placebo control. The depressive symptoms tended to improve... 

A prospective, randomized, placebo-controlled trial of paroxetine in adults with chronic post-traumatic stress disorder (PTSD) was recently conducted (Marshall etal., 2007). The subjects were New Yorkers, predominantly female (67%) and Hispanic (65.4%). Seventy subjects entered the study and after a one week placebo lead-in, 52 subjects were randomized to placebo or paroxetine for ten weeks. The subjects were treated with a flexible dosage design (mean dosage, 40.4 mg/day). Dropout rates were 32% for paroxetine and 51.9% for placebo. There were no differences in rates of adverse effects between treatment arms. Paroxetine was superior to placebo in ameliorating the primary symptoms of PTSD (56% vs. 22.2%). 

The results from an open-label, pilot study evaluating the efficacy of fluvoxamine for hypochondriasis were recently published (Fallon et al, 2003). The study sample included six Hispanics (subgroup unknown). Significant improvement (57.1%) was noted for the intent-to-treat group (eight out of fourteen) based on physicianrated and self-rated scales. The sample size was too small to identify differences in response or adverse effects by ethnicity. 

A large open-label flexible dose study (Sanchez-Lacay etal, 2001) utilizing nefa-zodone in the treatment of major depression in a predominantly monolingual, Hispanic Caribbean population (Dominican Republic, Puerto Rico, and Cuba) revealed similar response rates and an endpoint mean dosage when compared to previous nefazodone trials with non-Hispanic patients. No serious adverse events were reported, but 42% of the subjects did not complete the study for various reasons including side effects, family, or work responsibilities. 

Second, while we applaud the fact that more Hispanics are being included in clinical studies, the sample sizes continue to be small, limiting the interpretations that can be made from the data. In some cases, multiple studies have been pooled together to increase the Hispanic sample size. This is methodologically less rigorous as there may be variability in the methods employed between studies, for example inter-rater differences. 

Fifth, the increased risk of obesity and diabetes mellitus in Hispanics warrants careful consideration of SGA use in this population. Although there is variance in the data from studies assessing the incidence of metabolic syndrome in Hispanics being administered SGAs, one study pointed to a significantly higher incidence compared to non-Hispanics. Further research in this area is warranted. 

Alonso, M., Val, E. Rapaport, M. H. (1997). An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. /. Clin. Psychiatry, 58, 31. 

Currier, M. B., Molina, G. 8c Kato, M. (2004). Citalopram treatment of major depressive disorder in Hispanic HIV and AIDS patients a prospective study. Psychosomatics, 45, 210-16. 

Cardiovascular Effects. There is currently considerable scientific debate as to whether there is a causal relationship between lead exposure and hypertension. Another area of controversy is whether African Americans are more susceptible to the cardiovascular effects of lead than are whites or Hispanics. The evidence from both occupational studies and large-scale general population studies (i.e., National Health and Nutrition Examination Survey [NHANES II], British Regional Heart Study [BRHS]) is not sufficient to conclude that such a causal relationship exists between PbB levels and increases in blood pressure. The database on lead-induced effects on cardiovascular function in humans will be discussed by presenting a summary of several representative occupational studies followed by a discussion of the findings from the large-scale general population studies. 

Lead-containing ceramic ware used in food preparation has also been associated with childhood lead exposure in children of Hispanic ethnicity in San Diego County, California. One study (Gersberg et al. 1997) used the IEUBK to determine that dietary lead exposure from beans prepared in Mexican ceramic bean pots may account for a major fraction of blood lead burden in children whose families use such ceramic ware. 

One study documented the paucity of opioid pharmaceuticals in low-income neighborhoods consisting primarily of African Americans and Hispanic Americans as evidence of barriers to adequate pain management among populations... 

Arroyo, J. A., Miller, W. R., Tonigan, J. S. (2003). The influence of Hispanic ethnicity on long-term outcome in three alcohol-treatment modalities. Journal of Studies on Alcohol, 64, 98-104. 

Insulin-dependent posttransplant diabetes mellitus (PTDMj. lnsulin-dependent PTDM was reported in 20% of tacrolimus-treated kidney patients without pretransplant history of diabetes mellitus in the Phase 3 study. The median time to onset of PTDM was 68 days. Insulin dependence was reversible in 15% of these PTDM patients at 1 year and in 50% at 2 years posttransplant. Black and Hispanic kidney transplant patients were at an increased risk of development of PTDM. 

The official estimate in 1998 also includes a breakdown by race (table 9.8) Note that Hispanic is a special ethnic designation, and can be of any race. America is becoming less white, as most racial minorities are experiencing population increases faster than the whites. There is also the rise of the multi-racial population in America, which will be included in future population classifications as a separate category. All these characteristics and changes in the population are important, as marketers need to study the consumption preferences of each segment of the population. 

---